“…CAR-T cells combined with olaparib at the dose of 50 mg/kg/day could suppress tumor progress in mice bearing EGFRvIII-positive cell xenografts. Previous studies showed that the mutation rate of BRCA1/2 only reaches 12.2% in breast cancers and 25% in triple-negative breast cancers, 32 which limits clinical use of PARPi. However, our data demonstrated that CAR-T cells combined with olaparib might be applied in treating breast cancers without BRCA1/2 deficiency.…”